TY - JOUR
T1 - mTORC1 shutdown unleashes TFEB to drive triple-negative breast cancer invasion
AU - Gounis, Michalis
AU - Hamidi, Hellyeh
AU - Ivaska, Johanna
PY - 2025/4/7
Y1 - 2025/4/7
N2 - The PI3K/AKT/mTOR pathway is considered a key therapeutic target in triple-negative breast cancer (TNBC). In this issue of Developmental Cell, Remy et al. challenge this idea by demonstrating that mTORC1 inhibition activates TFEB, promoting MT1-MMP exocytosis, ECM degradation, and increased cell invasion, especially when combined with chemotherapy.
AB - The PI3K/AKT/mTOR pathway is considered a key therapeutic target in triple-negative breast cancer (TNBC). In this issue of Developmental Cell, Remy et al. challenge this idea by demonstrating that mTORC1 inhibition activates TFEB, promoting MT1-MMP exocytosis, ECM degradation, and increased cell invasion, especially when combined with chemotherapy.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=aboakademi&SrcAuth=WosAPI&KeyUT=WOS:001468999900001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1016/j.devcel.2025.03.006
DO - 10.1016/j.devcel.2025.03.006
M3 - Editorial
C2 - 40199239
SN - 1534-5807
VL - 60
SP - 979
EP - 981
JO - Developmental Cell
JF - Developmental Cell
IS - 7
ER -